<DOC>
	<DOCNO>NCT01292525</DOCNO>
	<brief_summary>The main objective study demonstrate benefit withdrawal Tacrolimus ( Prograf® ) renal function patient one year end weaning period . The secondary objective focus assess risk consequence withdrawal Tacrolimus ( Prograf® ) .</brief_summary>
	<brief_title>Protocol Calcineurin Inhibitor ( CNI ) Weaning</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>Preinclusion criterion : Male female age 18 80 year ( inclusive ) , Having receive deceased donor transplant live ABO compatibility , First renal allograft least 4 year 10 year , Presenting stable renal function : serum creatinine variation ± 25 % average year inclusion , Treated tacrolimus ( Prograf® ) combination MPA ( Cellcept® Myfortic® ) + / steroid ( 5 10 mg per day ) , Patient give informed consent , Patient insure , Patient ( childbearing age ) effective contraception . Glomerular Filtration Rate ( GFR ) , define dosage cystatin C ≥ 40 ml/min/1 , 73m² , Proteinuria ≤ 0,5 g / day , Patient serum level Tacrolimus 5 10 ng / ml average last 6 month ( inclusive ) . It accept 25 % assay perform last 6 month , serum level tacrolimus outside limit mention ( 510 ng / ml ) . They must nevertheless 3.5 12.5 ng / ml ( inclusive ) . Patient serum level MPA ( Cellcept® Myfortic® ) high ≥ 30 mg / ml , No antiHLA antibody time inclusion , verify use highly sensitive technique ( Luminex HD ) , Lack histological evidence cellular humoral acute chronic subclinical rejection renal graft accord late classification Banff 2009 . Patients age 18 80 year , Transplanted less 4 year 10 year , Patients retransplanted , Transplantation several organ , Patient treat tacrolimus maintenance therapy , Serum level Tacrolimus patient &lt; 5 &gt; 10 ng / ml , Serum level MPA patient &lt; 30 mg / ml , Patients treat immunosuppressive drug Tacrolimus ( Prograf® ) , MPA ( Cellcept® Myfortic® ) steroid , Patient stable graft function baseline ( change serum creatinine &gt; 25 % average year inclusion study ) , GFR define dosage cystatin C &lt; 40 ml/min/1 , 73m² time inclusion , Patients proteinuria &gt; 0.5 g study entry , Patient HLA antibody study entry , Patient noncompliant , Presence histological evidence cellular humoral acute chronic subclinical rejection renal graft accord late classification Banff 2009 , History lymphoproliferative disorder , Diagnosis malignancy within 5 year enrollment , Significantly abnormal hematologic data clinical standpoint , determine investigator hematocrit , hemoglobin , white blood cell count platelet , Data significantly abnormal blood biochemistry clinical standpoint , determine investigator , Abuse significant drug alcohol time inclusion , determine investigator , Patient positive antibody hepatitis C hepatitis B surface antigen hepatitis B ( HBsAg ) HIV infection , Participation clinical study within 3 month , Pregnancy , Breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Withdrawal Tacrolimus renal graft</keyword>
	<keyword>renal allograft</keyword>
	<keyword>stable renal function</keyword>
</DOC>